Drugs

Drugs

Breakthroughs in Cancer Therapy: Insights from New Studies on Angiogenesis Inhibitors

Scientists in the United States and People's Republic of China have made significant advancements in cancer therapy by exploring novel angiogenesis inhibitors, compounds that can halt the growth of new blood vessels that feed tumors, thereby preventing cancer progression and metastasis. Recent studies have shed light on the

Drugs

DNA Tumor Viruses: A Promising Approach to Cancer Cell Programming and Therapy

Scientists are exploring the use of DNA tumor viruses to understand cancer cell programming and develop therapeutic strategies to target tumor cells. Recent research suggests that these viruses can provide valuable insights into the molecular lesions that drive tumorigenesis and maintenance. Additionally, DNA tumor viruses have the potential to trigger

Drugs

Advances in Oncology: New Findings from China, Japan, and South Korea

Researchers from the People's Republic of China, Japan, and South Korea have made significant advancements in oncology, including the development of orally administered bacteria that transport anticancer genes in mice, the use of an anti-endostatin antibody to study its effectiveness in fighting liver cancer, and the aerosol delivery

Drugs

Targeting Cancer Angiogenesis: New Therapies for Tumor Growth and Invasion

Pioneering research from Ireland and the United States has shed new light on cancer therapy, focusing on the intricate relationship between cancer cell growth and angiogenesis. Investigators have identified peptides and proteins that can harness the power of vascular endothelial growth factor (VEGF) to selectively kill cancer cells, while also

Drugs

Insights into Oncogenesis: New Data from Switzerland, China, and the UK

Research investigators from Switzerland, China, and the UK have made significant contributions to the understanding of oncogenesis, shedding light on the molecular mechanisms that govern cancer development. A comprehensive review by Ernst Hafen, published in the Swiss Medical Weekly, provides insight into the role of model organism genetics in understanding

Pharmaceutical industry

FDA Accepts Filing for Exubera, a Novel Inhaled Insulin Product

Diabetes has become a major public health issue, affecting nearly 180 million people worldwide, with the number expected to rise to 300 million in the next 20 years. Currently, diabetes and its complications account for more than $100 billion in healthcare costs annually in the United States. To address this

Pharmaceutical industry

Cellular Genomics, Inc. Achieves Key Milestone in Kinase Discovery Program

Cellular Genomics, Inc. (CGI) has announced the completion of a critical performance milestone in its joint kinase discovery program with Serono, a pharmaceutical company. The milestone relates to the successful development of CGI's unique in vivo models for kinase drug discovery, a breakthrough made possible by the company&

Pharmaceutical industry

Chiron's Liverpool Plant Cleared to Supply Flu Vaccines After Contamination Concerns

British regulators yesterday lifted a suspension on Chiron's Liverpool plant, allowing the company to restart manufacturing flu vaccines, following satisfactory changes and pledges to provide weekly updates. This decision is crucial in preventing a severe flu vaccine shortage in the US for the 2005-2006 season. Chiron and Sanofi-Aventis

Pharmaceutical industry

FDA Advisory Committee Votes Raise Questions About Industry Ties

Critics are questioning the Food and Drug Administration's (FDA) handling of conflicts of interest after a recent advisory committee vote on the safety of certain painkillers, including Vioxx and Bextra. The 17-15 and 17-13 votes, with two abstentions, in favor of Vioxx and Bextra, respectively, have sparked concerns

United States. Food and Drug Administration

FDA to Review Lung Cancer Drug Iressa's Effectiveness Amid Concerns Over Fast-Track Approval Process

Liz Szabo writes that an FDA advisory panel will review recent research showing that the lung cancer drug Iressa, which received fast-track approval two years ago, fails to improve survival. The drug, approved in 2003, was given accelerated approval on the condition that its maker conduct additional studies to confirm

United States. Food and Drug Administration

Clinicaltrials.gov Sees 300% Increase in Listings, but Quality Remains a Concern

Theresa Toigo, director of FDA's Office of Special Health Issues, reported a significant increase in the number of clinical trials submitted to the Clinicaltrials.gov database since September. However, she emphasized that the quality of these listings remains a concern. Toigo cited the International Committee of Medical Journal

Pharmaceutical industry

International Aid Responds to Disease Outbreak Threat with $4.6 Million in Pharmaceuticals

Tsunami relief efforts are shifting from rescue to recovery, but a new concern is emerging: the threat of highly communicable diseases. With over 500,000 people in refugee camps in the Banda Aceh area, International Aid is racing against time to prevent widespread outbreaks. The organization is shipping vital pharmaceuticals